Systemic treatment strategies for triple-negative breast cancer

World Journal of Clinical Oncology

Volumn 5, Issue 2, 2014, Pages 125-133

  Yadav, Budhi Singh ^a   Sharma, Suresh C ^a   Chanana, Priyanka ^a   Jhamb, Swaty ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Basal like; BRCA1; Breast cancer; Chemotherapy; Poly (ADP ribose) polymerase 1; Targeted therapy; Triple negative

Indexed keywords

EID: 84911361901     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i2.125     Document Type: Review

References (59)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277-300 [DOI: 10.3322/caac.20073]
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752 [PMID: 10963602 DOI: 10.1038/35021093]
3. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281 [DOI: 10.1200/JCO.2007.14.4147]
4. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002; 39: 608-610 [PMID: 12161606 DOI: 10.1136/jmg. 39.8.608]
5. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334 [PMID: 17438091 DOI: 10.1158/1078-0432.CCR-06-1109]
6. Hudis C, Citron M, Berry D, Cirrincione C, Gradishar W, Davidson N, Martino S, Livingston R, Ingle J, Perez E, Abrams J, Schilsky R, Ellis M, Muss H, Norton L, Winer E. Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective [abstract 41] . Breast Cancer Res Treat 2005; 94 (Suppl 1): S20-S21
7. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen Y, Giri D, Veer L, Hylton N. Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012; 30: 3242-3249 [PMID: 22649152]
8. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357: 1496-1506 [PMID: 17928597 DOI: 10.1056/NEJMoa071167]
9. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric- Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal status and clinical outcomes in a large cohort of patients with triplenegative breast cancer. J Clin Oncol 2011; 29: 2628-2634 [PMID: 21606433 DOI: 10.1200/JCO.2010.32.1877]
10. Skrypnikova M, Frolova M, Ignatova E, Pokataev I, Stenina M, Tjulandin S. Primary systemic therapy with metronomic doxorubicin, cyclophosphamide, and capecitabine in locally advanced and metastatic triple-negative breast cancer. J Clin Oncol 2011; 29: 1110
11. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685 [PMID: 16115903 DOI: 10.1158/1078-0432.CCR-04-2421]
12. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-2313 [PMID: 15930421 DOI: 10.1056/NEJMoa043681]
13. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008; 26: 44-53 [PMID: 18165639 DOI: 10.1200/JCO.2007.11.3787]
14. Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006; 24: 5381-5387 [PMID: 17135639 DOI: 10.1200/JCO. 2006. 06.5391]
15. Jacquemier J, Penault-Llorca F, Mnif H, Charafe-J E, Marque S, Martin A. Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissuemicroarray. J Clin Oncol (Meeting Abstracts) 2006; 24: 509
16. Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Abad M, Domínguez S, Florián J, Llorca C, Méndez M, Godes M, Cubedo R, Murias A, Batista N, García MJ, Caballero R, de Alava E. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat 2010; 123: 149-157 [PMID: 20037779 DOI: 10.1007/s10549-009-0663-z]
17. Loesch D, Greco F, O'Shaughnessy J. A randomized, multicenter, phase III trial comparing regimens of doxorubicin cyclophosphamide (AC) followed by paclitaxel to doxorubicin paclitaxel (AP) followed by weekly paclitaxel (wP) as adjuvant therapy for patients with high-risk, operable breast cancer. J Clin Oncol 2007; 25 (Suppl 18): 517
18. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-1671 [PMID: 18420499 DOI: 10.1056/NEJMoa0707056]
19. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 2010; 70: 7970-7980 [PMID: 20798217 DOI: 10.1158/0008-5472. CAN-09-4521]
20. Garber JF, Richardson A, Harris LN. Neo-adjuvant cisplatin (CDDP) in 'triple negative' breast cancer (BC). Breast Cancer Res Treat 2006; 100 (Suppl 1): S32
21. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, Nicolo AD, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. J Clin Oncol 2010; 28: 1145-1153 [DOI: 10.1200/JCO.2009.22.4725]
22. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379 [PMID: 20008645 DOI: 10.1200/JCO.2008.20.7019]
23. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, Kladny J, Gorski B, Lubinski J, Narod SA. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009; 115: 359-363 [PMID: 18649131 DOI: 10.1007/s10549-008-0128-9]
24. Ryan PD, Tung NM, Isakoff SJ, Golshan M, Richardson A, Corben AD, Smith BL, Gelman R, Winer EP, Garber JE. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. J Clin Oncol 2009; 27: 551
25. Frasci G, Comella P, Rinaldo M, Iodice G, Di Bonito M, D' Aiuto M, Petrillo A, Lastoria S, Siani C, Comella G, D'Aiuto G. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 2009; 20: 1185-1192 [PMID: 19218307 DOI: 10.1093/annonc/mdn748]
26. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008; 19: 1847-1852 [PMID: 18567607 DOI: 10.1093/annonc/mdn395]
27. Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, Gass JS, Kennedy TA, Fenton MA. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol 2009; 27: 4693-4700 [PMID: 19720916 DOI: 10.1200/JCO.2008.21.4163]
28. Leone J, Guardiola V, Venkatraman A. Neoadjuvant platinbased chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): retrospective analysis of 125 patients. J Clin Oncol 2009; 27: 625
29. Fountzilas G, Kalofonos HP, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P, Kalogera-Fountzila A, Gogas H, Aravantinos G, Moulopoulos LA, Economopoulos T, Pectasides D, Maniadakis N, Siafaka V, Briasoulis E, Christodoulou C, Tsavdaridis D, Makrantonakis P, Razis E, Kosmidis P, Skarlos D, Dimopoulos MA. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol2004; 15: 1517-1526 [PMID: 15367413 DOI: 10.1093/annonc/mdh395]
30. Heinemann V. Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clin Breast Cancer 2002; 3 Suppl 1: 24-29 [PMID: 12057042]
31. Maisano R, Zavettieri M, Azzarello D, Raffaele M, Maisano M, Bottari M, Nardi M. Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study. J Chemother 2011; 23: 40-43 [PMID: 21482494]
32. Koshy N, Quispe D, Shi R, Mansour R, Burton GV. Cisplatin - gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 2010; 19: 246-248 [PMID: 20227277 DOI: 10.1016/j.breast.2010.02.003]
33. Staudacher L, Cottu PH, Diéras V, Vincent-Salomon A, Guilhaume MN, Escalup L, Dorval T, Beuzeboc P, Mignot L, Pierga JY. Platinum-based chemotherapy in metastatic triplenegative breast cancer: the Institut Curie experience. Ann Oncol 2011; 22: 848-856 [PMID: 20924076 DOI: 10.1093/annonc/mdq461]
34. Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, Makhson A, Tjulandin S, Ludwig H, Verrill M, Ciruelos E, Egyhazi S, Xu LA, Zerba KE, Lee H, Clark E, Galbraith S. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009; 27: 526-534 [PMID: 19075286 DOI: 10.1200/JCO.2007.14.2646]
35. Pivot XB, Li RK, Thomas ES, Chung HC, Fein LE, Chan VF, Jassem J, de Mendoza FH, Mukhopadyay P, Roché HH. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. Eur J Cancer 2009; 45: 2940-2946 [PMID: 19683429 DOI: 10.1016/j.ejca.2009.07.015]
36. Rugo HS, Thomas E, Lee R, Fein LE, Peck R, Verrill M. Combination therapy with novel epothiolone B analog, ixabepilone, plus capecetabine has efficacy in ER/PR/HER2- negative breast cancer resistant to anthracyclins and taxanes. Breast Cancer Res Treat 2007; 106: S270-S270
37. Roche H, Li R, Ro J, Vrdoljak E, Rahman ZU, Medina C, Conte P, Volles LA, Poulart V, Sparano JA. Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials. Cancer Res 2009; 69 (Suppl 2): 2015
38. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244 [PMID: 20609467 DOI: 10.1016/S0140-6736(10)60892-6]
39. Dent R, Lindeman G, Clemons M, Wildiers H, Chan A, Mc- Carthy N, Singer C, Lowe E, Kemsley K, Carmichael J. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 2010, 28: 118s
40. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-214 [PMID: 21208101 DOI: 10.1056/NEJMoa1011418]
41. O'Shaughnessy J, Schwartzberg LS, Danso MA, Rugo HS, Miller K, Yardley DA. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29: 81
42. Isakoff SJ, Overmoyer B, Tung NM, Gelman RS, Giranda VL, Bernhard KM, Habin KR, Winer EP, Goss PE. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolamide for metastatic breast cancer [abstract 1019] J Clin Oncol 2010; 28: 1019
43. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94: 1593-1611 [PMID: 11920518]
44. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30: 2615-2623 [PMID: 22665533 DOI: 10.1200/JCO.2010.34.5579]
45. O'Shaughnessy J, Weckstein DJ, Vukelja SJ, McIntyre K, Krekow L, Holmes FA, Asmar L, Blum JL. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007; 106: S32-S33
46. Baselga J, Stemmer S, Pego A, Chan A, Goeminne J-C, Graas M-P, Kennedy J, Ciruelos Gil EM, Zubel A, Groos J, Kia U, Schneeweiss A. Abstract [PD01-01] Cetuximab Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial. Cancer Research 2010; 70 [DOI: 10.1158/0008-5472.SABCS10- PD01-01]
47. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, Justice R, Pazdur R. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008; 13: 1114-1119 [PMID: 18849320 DOI: 10.1634/theoncologist. 2008-0816]
48. Cristofanilli M, Boussen H, Baselga J. A phase II combination study of lapatinib and paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Presented at: 29th annual San Antonio breast cancer symposium, 2006
49. Finn RS, Bengala C, Ibrahim N, Strauss LC, Fairchild J, Sy O, Roche H, Sparano J, Goldstein LJ. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA 180059. Cancer Res 2009; 69: 237S
50. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27: 4966-4972 [DOI: 10.1200/JCO. 2008.21.6630]
51. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM,Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247 [DOI: 10.1200/JCO.2008.21.6457]
52. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260 [DOI: 10.1200/JCO.2010.28.0982]
53. Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, Rivera R, Duenne A, Bousfoul N, Yardley DA. Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2. J Clin Oncol 2011; 29: 1010
54. Gerber B, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch CA, Kreienberg R, Solbach C, Jackisch C, Kunz G, Blohmer JU, Huober JB, Hauschild M, Loibl S, Nekljudova V, Untch M, Von Minckwitz G, GBG/AGO study groups. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44). J Clin Oncol 2011; 29: 1006
55. Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C. Firstline treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012; 30: 921-929 [PMID: 22331954 DOI: 10.1200/JCO.2011.35.7376]
56. Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C, Kreienberg R, Miller WH, Tassell V, Huang X, Paolini J, Kern KA, Romieu G. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013; 31: 2870-2878 [PMID: 23857972 DOI: 10.1200/JCO.2012.43.3391]
57. Baselga J, Roche H, Costa F. SOLTI 0701: a multinacional double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer [abstract 45] . In Proceedings of the 32nd Annual San Antonio Breast Cancer Symposium, 2009
58. Gradishar W, Kaklamani V, Prasad Sahoo T. A Double- Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC). Cancer Res 2009; 69: 44 [DOI: 10.1158/0008-5472.SABCS-09-44]
59. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, Brown E N, Lee R T, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011; 29: 2645-2652 [DOI: 10.1200/JCO.2010.33.4441]